SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : TNXP (MC $30 M) (Cash $34 M) O/S 7.5 M / P3 Data in 1H 2018

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: BioHero9/28/2017 9:12:31 AM
   of 12
 
IF P3 is successful then this stock could hit $80-100 per share (= Mcap $600-750M) thats not much for a Drug with $650 million potential.GL

Tonix's Tonmya Treats PTSD By Helping Sufferers Sleep Better ..Sep.27.17
seekingalpha.com

Summary

PTSD is a serious illness that has devastating symptoms. It affects 3.5% of American adults, or 8.6m individuals each year. The prevalence of PTSD is even higher among veterans.

The only FDA approved PTSD drug treatment, the SSRIs (selective serotonin reuptake inhibitors), failed to show efficacy in military-related PTSD and have serious side effects.

Tonix's Tonmya is being studied in HONOR, a phase 3 trial for treating military-related PTSD. Tonmya works by improving sleep quality and allowing the mind to heal itself.

This article focuses on PTSD and discusses how Tonmya can meet a very important unmet medical need.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext